Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

142.62 USD +7.73 (+5.73%)
Official Closing Price Updated: 7:44 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Ligand Pharm

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered a worldwide OmniAb platform license agreement with Glenmark Pharmaceuticals. Under the license, Glenmark will be able to use... 
From Business Wire News Releases
Ligand Earns $6 Million as OmniAb Partner Out-Licenses Antibody Projects
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner HanAll Biopharma successfully out-licensed antibody projects that were discovered by HanAll using Ligand’s OmniAb® antibody... 
From Business Wire News Releases
Detailed Research: Economic Perspectives on MACOM Technology Solutions, Whirlpool, Dril-Quip, Ligand Pharmaceuticals, National CineMedia, and F5 Networks — What Drives Growth in Today's Competitive La
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MACOM Technology Solutions... 
From GlobeNewswire News Releases
Ligand Provides Highlights from Today’s Analyst Day Event
At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business, including its revenue growth opportunities, its... 
From Business Wire News Releases
Ligand Reports Third Quarter 2017 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2017, and provided an operating forecast and program updates. 
From Business Wire News Releases
Reminder: Ligand to Host Analyst Day on November 14th in New York City
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, November 14, 2017 from 4:00 p.m. to 5:30 p.m. Eastern time (1:00 p.m. to 2:30 p.m. Pacific time) in New York... 
From Business Wire News Releases
Ligand to Participate in the Stephens Fall Investment Conference
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the Stephens Fall Investment Conference in New York City. Presentation takes place on... 
From Business Wire News Releases
Ligand to Report Third Quarter 2017 Results on November 9th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it plans to report third quarter 2017 financial results after market close on November 9, 2017 and to provide additional... 
From Business Wire News Releases
Ligand to Acquire Crystal Bioscience, the Leader in Chicken-derived Fully-human Antibody Generation, for $25 Million in Cash plus Additional Potential Payments
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Crystal Bioscience, Inc. (Crystal) announce the signing of a merger agreement whereby Ligand will acquire Crystal, a leader in avian genetics and... 
From Business Wire News Releases
Ligand to Host Analyst Day on November 14th in New York City
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, November 14, 2017 from 4:00 p.m. to 5:30 p.m. Eastern time (1:00 p.m. to 2:30 p.m. Pacific time) in New York... 
From Business Wire News Releases
Ligand Announces Top-Line Results from Phase 2 Study of LGD-6972 in Patients with Type 2 Diabetes
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced positive top-line results from a Phase 2 clinical study evaluating the efficacy and safety of LGD-6972, as an adjunct to diet and... 
From Business Wire News Releases
Ligand to Participate in Two Upcoming Investor Conferences
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: 
From Business Wire News Releases
Ligand Appoints Dr. Nancy Gray to its Board of Directors
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Nancy Ryan Gray, Ph.D. to the Company’s Board of Directors, effective today. Dr. Gray... 
From Business Wire News Releases
Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb® Technology
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces that it will receive a $2 million payment from WuXi Biologics subsequent to their licensing of exclusive rights... 
From Business Wire News Releases
Ligand Reports Second Quarter 2017 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2017, and provided an operating forecast and program updates. Ligand... 
From Business Wire News Releases
Investor Network: Ligand Pharmaceuticals Incorporated to Host Earnings Call
From ACCESSWIRE
Ligand to Report Second Quarter 2017 Results on August 7th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2017 financial results on August 7, 2017. Ligand’s CEO John Higgins, President and COO Matt Foehr and... 
From Business Wire News Releases
Ligand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has entered into a commercial license and supply agreement with Amgen, granting rights to use Ligand’s Captisol technology in... 
From Business Wire News Releases
Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that partner Melinta Therapeutics, a privately held company focused on discovering, developing, and commercializing novel antibiotics to... 
From Business Wire News Releases
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Surface Oncology
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Cambridge, Massachusetts-based Surface Oncology. Under the license, Surface will be... 
From Business Wire News Releases
Ligand Announces Aziyo Biologics Acquires Commercial Products from Partner CorMatrix
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it will receive $10 million from a contractually specified royalty rate buy-down following the sale by CorMatrix Cardiovascular, Inc. of... 
From Business Wire News Releases
Ligand Enters Into Worldwide OmniAb® Platform License Agreement With xCella Biosciences
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces it has entered into a worldwide license agreement with Menlo Park, California-based xCella Biosciences, Inc. Under the license, xCella will... 
From Business Wire News Releases
Ligand to Participate in Two Upcoming Investor Conferences
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: 
From Business Wire News Releases
Ligand Reports First Quarter 2017 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2017, and provided an operating forecast and program updates. Ligand management... 
From Business Wire News Releases
Ligand to Report First Quarter 2017 Results on May 9th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2017 financial results on May 9, 2017. Ligand’s CEO John Higgins, President and COO Matt Foehr and CFO... 
From Business Wire News Releases
Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has entered into commercial License and Supply Agreements (License Agreement) with Marinus Pharmaceuticals, Inc., granting... 
From Business Wire News Releases
Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the OmniAb® Technology
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that CNA Development LLC, an affiliate of Janssen Pharmaceuticals, Inc. (Janssen) has filed an IND for an antibody discovered using Ligand’s... 
From Business Wire News Releases
Ligand to Participate in Upcoming Investor Conference
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conference: 
From Business Wire News Releases
Ligand Provides Highlights from Today’s Analyst Day Event
At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reviewed the recent progress of its business, its revenue growth opportunities and its portfolio... 
From Business Wire News Releases
Ligand Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that it has expanded its license with Sermonix Pharmaceuticals to include worldwide rights to develop and commercialize oral lasofoxifene.... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.